Gilead Sciences, Inc. (NASDAQ:GILD) CEO Sells $1,139,400.00 in Stock

Key Points

• Gilead Sciences CEO Daniel Patrick O'day sold 10,000 shares of stock at an average price of $113.94, totaling $1,139,400, reducing his ownership by 1.62%.
• As of the latest trading, Gilead shares rose 1.1% to $114.23, with a market cap of $142.09 billion and a P/E ratio of 24.05.
• Institutional investors now hold 83.67% of Gilead's stock, indicating strong institutional interest and potential confidence in the company’s future performance.

Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction on Monday, July 28th. The stock was sold at an average price of $113.94, for a total transaction of $1,139,400.00. Following the sale, the chief executive officer owned 605,725 shares in the company, valued at $69,016,306.50. This represents a 1.62% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Daniel Patrick O'day also recently made the following trade(s):

• On Monday, June 30th, Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock. The stock was sold at an average price of $110.45, for a total transaction of $1,104,500.00.
• On Friday, May 30th, Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock. The shares were sold at an average price of $110.42, for a total value of $1,104,200.00.

Gilead Sciences Stock Down 2.2%

Shares of GILD traded down $2.53 on Thursday, hitting $112.23. The company's stock had a trading volume of 3,953,570 shares, compared to its average volume of 8,423,339. The company has a quick ratio of 1.23, a current ratio of 1.37 and a debt-to-equity ratio of 1.16. The firm's fifty day moving average price is $110.29 and its 200-day moving average price is $106.39. Gilead Sciences, Inc. has a fifty-two week low of $72.43 and a fifty-two week high of $119.96. The firm has a market capitalization of $139.60 billion, a price-to-earnings ratio of 23.68, a P/E/G ratio of 0.72 and a beta of 0.29.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on GILD shares. Morgan Stanley lifted their price objective on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Needham & Company LLC raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target for the company in a report on Friday, July 25th. Cantor Fitzgerald began coverage on Gilead Sciences in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price target for the company. Finally, Oppenheimer cut their price target on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, April 25th. Eight analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $112.36.

Institutional Investors Weigh In On Gilead Sciences

Several institutional investors have recently bought and sold shares of the company. Southland Equity Partners LLC lifted its stake in Gilead Sciences by 2.9% in the 2nd quarter. Southland Equity Partners LLC now owns 3,285 shares of the biopharmaceutical company's stock valued at $364,000 after acquiring an additional 92 shares in the last quarter. Redwood Financial Network Corp lifted its stake in Gilead Sciences by 4.0% in the 4th quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company's stock valued at $234,000 after acquiring an additional 98 shares in the last quarter. Twelve Points Wealth Management LLC lifted its stake in Gilead Sciences by 1.5% in the 2nd quarter. Twelve Points Wealth Management LLC now owns 6,499 shares of the biopharmaceutical company's stock valued at $721,000 after acquiring an additional 98 shares in the last quarter. Argentarii LLC lifted its stake in Gilead Sciences by 3.0% in the 1st quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company's stock valued at $380,000 after acquiring an additional 99 shares in the last quarter. Finally, Nicolet Advisory Services LLC lifted its stake in Gilead Sciences by 2.9% in the 4th quarter. Nicolet Advisory Services LLC now owns 3,580 shares of the biopharmaceutical company's stock valued at $322,000 after acquiring an additional 100 shares in the last quarter. Institutional investors own 83.67% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.